<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20040506113503+02'00'</creation_date><modification_date>D:20040506113503+02'00'</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-1-04-273_h_a_dec_0.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header><p>commission of the european communities</p><p>brussels, 28-iv-2004 c(2004) 1765 
 not for publication</p></section><section><header>commission decision of 28-iv-2004 
 granting the marketing authorization for the orphan medicinal product for human 
 use &quot;lysodren - mitotane&quot; under council regulation (eec) no 2309/93</header><p>only the french text is authentic</p></section><section><header>en  
   en</header></section><section><header>commission decision of 28-iv-2004 
 granting the marketing authorization for the orphan medicinal product for human 
 use &quot;lysodren - mitotane&quot; under council regulation (eec) no 2309/93 
 (text with eea relevance)</header><p>the commission of the european communities,</p><p>having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, as amended by commission regulation (ec) no 649/982, and in particular article 10(2) thereof,</p><p>
 having regard to regulation (ec) no 141/2000 of the european parliament and of the 
 council of 16 december 1999 on orphan medicinal products
 3, having regard to the application submitted by laboratoire hra pharma, on 18 
 november 2002, under article 4(1) of regulation (eec) no 2309/93,</p><p>
 having regard to the opinion of the european agency for the evaluation of medicinal 
 products, formulated by the committee for proprietary medicinal products on 21 january 
 2004,</p><p>
 whereas:</p><p>
 (1)</p><p>commission decision c(2002)2228 of 12 june 2002 designated &quot;mitotane&quot; as an 
 orphan medicinal product.</p><p>
 (2)</p><p>the orphan medicinal product &quot;lysodren - mitotane&quot; complies with the 
 requirements set out in directive 2001/83/ec of the european parliament and of 
 the council of 6 november 2001 on the community code relating to medicinal 
 products for human use
 4 as amended by directive 2002/98/ec5 and by directive 2003/63/ec
 6.</p><p>
 1 oj l 214, 24. 8. 1993, p. 1. 2 oj l 88, 24.3.1998, p. 7. 3 oj l 18, 22.1.2000, p. 1. 4 oj l 311, 28.11.2001, p. 67. 5 oj l 33, 8.2.2003, p. 30. 6 oj l 159, 27.6.2003, p. 46.</p></section><section><header>en  
   en</header><p>(3) it is therefore appropriate to authorise its placing on the market.</p><p>
 (4)</p><p>the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use,</p><p>
 has adopted this decision:</p><p>
 article 1</p><p>the marketing authorisation referred to in article 3 of regulation (eec) no 2309/93 is hereby granted for the orphan medicinal product &quot;lysodren - mitotane&quot;, whose 
 characteristics are summarised in annex i hereto. this orphan medicinal product is 
 registered in the community register of medicinal products under nos:</p><p>
 eu/1/04/273/001 
 lysodren - 500 mg - tablet - oral use - bottle (hdpe) (glass) - 100 
 tablets 
 article 2</p><p>the marketing authorization concerning the medicinal product referred to in article 1 shall be subject to compliance with all the conditions, particularly those relating to 
 manufacture and importation, control and issue referred to in annex ii.</p><p>
 article 3</p><p>the labelling and package leaflet concerning the orphan medicinal product referred to in article 1 shall conform to annex iii.</p><p>
 article 4</p><p>the period of validity of the authorization issued shall be five years from the date of notification of this decision. it shall be renewable under the conditions laid down in 
 article 13(1) of regulation (eec) no 2309/93.</p><p>
 article 5</p><p>this decision is addressed to laboratoire hra pharma, 19, rue frédérick lemaitre, f-75020 paris, france.</p><p>
 done at brussels, 28-iv-2004</p><p>
 for the commission erkki liikanen 
 member of the commission</p></section></body></xml>